Implementing Multifactorial Risk Assessment with Polygenic Risk Scores for Personalized Breast Cancer Screening in the Population Setting: Challenges and Opportunities.

breast cancer breast cancer screening implementation polygenic risk score risk assessment risk stratification

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
31 May 2024
Historique:
received: 12 04 2024
revised: 11 05 2024
accepted: 18 05 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: epublish

Résumé

Risk-stratified breast screening has been proposed as a strategy to overcome the limitations of age-based screening. A prospective cohort study was undertaken within the PERSPECTIVE I&I project, which will generate the first Canadian evidence on multifactorial breast cancer risk assessment in the population setting to inform the implementation of risk-stratified screening. Recruited females aged 40-69 unaffected by breast cancer, with a previous mammogram, underwent multifactorial breast cancer risk assessment. The adoption of multifactorial risk assessment, the effectiveness of methods for collecting risk factor information and the costs of risk assessment were examined. Associations between participant characteristics and study sites, as well as data collection methods, were assessed using logistic regression; all

Identifiants

pubmed: 38893236
pii: cancers16112116
doi: 10.3390/cancers16112116
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Genome Canada
ID : 13529
Organisme : CIHR
ID : 155865
Pays : Canada
Organisme : Génome Québec
ID : N/A
Organisme : Quebec Breast Cancer Foundation
ID : N/A
Organisme : the CHU de Québec Foundation
ID : N/A
Organisme : CHU de Québec-Université Laval Research Center
ID : N/A
Organisme : Ontario Research Fund
ID : N/A
Organisme : Cancer Research UK
ID : PPRPGM-Nov20\100002
Pays : United Kingdom

Auteurs

Meghan J Walker (MJ)

Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.

Kristina M Blackmore (KM)

Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.

Amy Chang (A)

Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.

Laurence Lambert-Côté (L)

CHU de Québec-Université Laval Research Center, Queébec City, QC G1V 4G2, Canada.

Annie Turgeon (A)

CHU de Québec-Université Laval Research Center, Queébec City, QC G1V 4G2, Canada.

Antonis C Antoniou (AC)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.

Kathleen A Bell (KA)

Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.

Mireille J M Broeders (MJM)

Department for Health Evidence, Radboud University Medical Center, 6525EP Nijmegen, The Netherlands.

Jennifer D Brooks (JD)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.

Tim Carver (T)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.

Jocelyne Chiquette (J)

CHU de Québec-Université Laval Research Center, Queébec City, QC G1V 4G2, Canada.
Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval, Québec City, QC G1V 0A6, Canada.

Philippe Després (P)

Department of Physics, Engineering Physics and Optics, Faculty of Science and Engineering, Université Laval, Quebec City, QC G1V 0A6, Canada.

Douglas F Easton (DF)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.

Andrea Eisen (A)

Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
Sunnybrook Health Science Center, Toronto, ON M4N 3M5, Canada.

Laurence Eloy (L)

Québec Cancer Program, Ministère de la Santé et des Services Sociaux, Quebec City, QC G1S 2M1, Canada.

D Gareth Evans (DG)

Division of Evolution Infection and Genomic Sciences, The University of Manchester, Manchester M13 9PL, UK.

Samantha Fienberg (S)

Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.

Yann Joly (Y)

Centre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.

Raymond H Kim (RH)

Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.

Shana J Kim (SJ)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.

Bartha M Knoppers (BM)

Centre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.

Aisha K Lofters (AK)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.
Women's College Research Institute, Toronto, ON M5G 1N8, Canada.

Hermann Nabi (H)

CHU de Québec-Université Laval Research Center, Queébec City, QC G1V 4G2, Canada.
Department of Social and Preventive Medicine, Faculty of Medicine, Université Laval, Quebec City, QC G1V 0A6, Canada.
Université Laval Cancer Research Center, Quebec City, QC G1R 3S3, Canada.

Jean-Sébastien Paquette (JS)

Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval, Québec City, QC G1V 0A6, Canada.

Nora Pashayan (N)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.
Department of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London WC1E 6BT, UK.

Amanda J Sheppard (AJ)

Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.

Tracy L Stockley (TL)

Division of Clinical Laboratory Genetics, University Health Network, Toronto, ON M5G 2C4, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.

Michel Dorval (M)

CHU de Québec-Université Laval Research Center, Queébec City, QC G1V 4G2, Canada.
Université Laval Cancer Research Center, Quebec City, QC G1R 3S3, Canada.
Faculty of Pharmacy, Université Laval, Quebec City, QC G1V 0A6, Canada.

Jacques Simard (J)

CHU de Québec-Université Laval Research Center, Queébec City, QC G1V 4G2, Canada.
Department of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec City, QC G1V 4G2, Canada.

Anna M Chiarelli (AM)

Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.

Classifications MeSH